AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse

AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse  CNBC

Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.